INO

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Is INO stock a buy after expanding its partnership with Advaccine to run a Phase 3 test of its Covid vaccine? Inovio stock soared on the news.

In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.

Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss progress in the fight against COVID-19.

The meme stock rally has taken off in recent weeks. Shares of everything from AMC Entertainment (AMC) to GameStop (GME) and BlackBerry (BB) have seen violent swings since late May. Investors in the most well-know meme stocks have certainly benefited from this recent surge. However, one of the more intriguing developments of late is the seeming expansion of the list of stocks retail traders are focusing on. Smaller, lesser-known companies are now making the cut. And Inovio Pharmaceuticals (INO) i

What happened Shares of Inovio Pharmaceuticals (NASDAQ: INO) were sinking 8.8% as of 11:13 a.m. EDT on Thursday. The company didn't announce any new developments, and today's sell-off appears to be due to investors taking profits after Inovio's shares jumped nearly 17% yesterday.

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced an expansion of its previously announced partnership with Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine") to jointly conduct a global Phase 3 segment of the ongoing Phase 2/3 trial called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy). Together, the companies will e

Inovio Pharmaceuticals Inc (NASDAQ: INO) has expanded its partnership with Advaccine Biopharmaceuticals Suzhou Co Ltd to jointly conduct a global Phase 3 part of the ongoing Phase 2/3 trial, INNOVATE, assessing its DNA COVID-19 vaccine candidate. The trial will evaluate the safety and efficacy of INO-4800 in a two-dose regimen (2.0 mg), administered one month apart, in two-to-one randomization in subjects 18 years and older across several countries, primarily in Latin America and Asia. The prima

Inovio Pharmaceuticals Inc on Tuesday expanded its partnership with Advaccine Biopharmaceuticals to conduct a late-stage trial of its COVID-19 vaccine candidate, expected to start in the summer. Inovio and Advaccine had entered into an agreement in January, under which Advaccine gained the exclusive right to develop and market the DNA vaccine, INO-4800, within Greater China. Under the expanded deal, the companies expect to equally share the total cost of the late-stage trial, expected to be about $100 million, Inovio said.

AL, FET, INO, SWKH, and WPG have been added to the Zacks Rank #5 (Strong Sell) List on June 7, 2021.

What happened Shares of the clinical-stage biotech Inovio Pharmaceuticals (NASDAQ: INO) gained a respectable 10.9% over the course of May, according to data provided by S&P Global Market Intelligence.

Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today positive preliminary results of its ongoing first-in-human trial. GT-30 is a phase I/II trial of personalized vaccine, GNOS-PV02, in combination with plasmid pIL-12 and pembrolizumab in patients in second line advanced hepatocellular carcinoma (HCC).

Is INO stock a sell after its midstage coronavirus vaccine test showed mixed results in mid-May and after the Department of Defense pulled its funding for Phase 3 testing?

While many coronavirus stocks soared to record highs over the past year, shares of Inovio Pharmaceuticals (NASDAQ: INO) are down nearly 50% over the past 12 months. The company has not advanced its DNA coronavirus vaccine INO-4800 to commercialization, and generally speaking, its research and development efforts have been a massive disappointment. Keep in mind that this company announced the discovery of a coronavirus vaccine after a mere three hours of effort during the early days of the pandemic.

INOVIO (NASDAQ:INO) a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced today that Dr. Joseph Kim, President and CEO, is scheduled to participate in a fireside chat and 1x1 investor meetings at the Jefferies 2021 Virtual Healthcare Conference on Tuesday, June 1, 2021 at 2:00 PM EDT. A webcast of the event will be available at this link: https://wsw.com/webcast/jeff174/ino/1702890.

Ocugen (NASDAQ: OCGN) and Inovio Pharmaceuticals (NASDAQ: INO) have both stirred up stock market excitement in recent times. Inovio's gain happened a year ago when it was a front-runner in the coronavirus vaccine race. Ocugen shares have soared nearly 400% this year after the company signed a deal to co-commercialize Bharat Biotech's near-to-market coronavirus vaccine in the U.S.

Inovio Pharmaceuticals (NASDAQ: INO) recently reported encouraging results from a phase 2 study of its COVID-19 vaccine candidate INO-4800. In this Motley Fool Live video recorded on May 12, Motley Fool contributors Keith Speights and Brian Orelli discuss Inovio's latest clinical results. Keith Speights: Inovio Pharmaceuticals reported its phase 2 results for its COVID-19 vaccine candidate, INO-4800, earlier this week, Brian, what were the highlights from Inovio's results?

The company initially lost momentum when the U.S. Food and Drug Administration (FDA) placed a partial clinical hold on one of its trials last fall. More recently, the government dropped a plan to fund its phase 3 trial.

INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the appointment of Roger D. Dansey, M.D. to its Board of Directors. The appointment adds extensive expertise in drug development to the INOVIO Board as the company strengthens its focus on its late stage product development programs. Currently the Chief Medical Officer at Seagen (formerly Seattle Genetics), Dr. Dansey has played a central role in Seagen's efforts to become a globally recognized, multi--product oncology company.

Inovio Pharmaceuticals (INO) has been playing catch up in the Covid-19 vaccine race for a while now. One of the early frontrunners, the biotech has been unable to get its DNA Covid-19 vaccine INO-4800 to Phase 3 testing yet. However, Oppenheimer’s Hartaj Singh thinks the latest update should change all that. Earlier this week, Inovio released data from the Phase 2 clinical trial which showed the vaccine was safe and also triggered antibody titers in around 400 adult patients. “The reported INO-4800's P2 binding/neutralizing antibody/T-cell response data are good enough to advance into a P3 trial,” the analyst said. “While efficacy is the most key aspect for a COVID vaccine, we believe INO-4800's high product stability (no need for cold chain storage/transport) is also vital, especially for the developing world and certain tropical areas. Safety/tolerability profile (AEs does not worsen upon 2-nd dose) also differentiates INO-4800.” Inovio has run into a brick wall with the vaccine’s development in U.S. as the FDA has still not approved the Phase 3 portion. Additionally, the DoD (Department of Defence) recently announced it will no longer provide funding for the late-stage study. But Inovio intends to commence with further testing abroad and has said it is “committed to initiate its global P3 trial as quickly as possible.” Singh thinks the trials should begin “around this summer.” The latest data has only increased Singh’s “conviction,” and the analyst highlights the fact that other Covid-19 vaccines which reported positive Phase 1 and 2 outcomes tend to “also work in P3.” Moreover, as the commercial focus has shifted from the U.S. to the international stage, Singh thinks there could be “opportunities to secure some advanced purchasing agreements as INO-4800's P3 starts.” The analyst signs off by telling investors to “buy on weakness of INO's stock.” Overall, Singh is Wall Street’s most prominent INO bull; his $35 price target indicates upside potential of 434%. Unsurprisingly, the analyst’s rating is an Outperform (i.e. Buy). (To watch Singh’s track record, click here) Looking at the rest of the Street’s take, the ratings breakdown to 5 Holds vs. 2 Buys, giving the stock a Moderate Buy consensus rating. The analysts have a bullish average price target; at $14.5, the shares are expected to appreciate by 122% over the next 12 months. (See Inovio stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.